Researchers demonstrated the significance of access to supportive and posttrial care as it relates to cancer survival among clinical trial participants.
In a phase 3 trial that included 1052 men with metastatic castration-sensitive prostate cancer, apalutamide plus androgen deprivation therapy (ADT) was associated with a 33% decreased risk of death compared with those who received placebo plus ADT.
In a phase 2 trial of men with metastatic castration-resistant prostate cancer, cabazitaxel plus carboplatin significantly prolonged progression-free survival compared with cabazitaxel alone.
The median time from first infusion of sipuleucel-T to death from prostate cancer was 42.7 months.
Study suggests that prostate mpMRI prior to radical prostatectomy for high-risk prostate cancer could lead to changes in surgical planning that may potentially affect patient outcomes.
The microbiome could have a role in the diagnosis of PrCa.
Confirmatory biopsy with MRI guidance provides a more accurate risk assessment than a conventional transrectal ultrasound confirmatory biopsy, according to researchers.
In a study, investigators observed a reduced probability of prostate cancer in nondiabetic men with greater use of testosterone therapy.
In a study, Japanese men who ate mushrooms each week had lower risk for prostate cancer.
Men who have bladder outlet obstruction (BOO) prior to robotic-assisted radical prostatectomy experience significant worsening of lower urinary tract function compared with men without BOO, a study found.